NASDAQ: AMEDAMEDISYS INC Stock
$117.21-3.94 (-3.25%)
Updated May 24, 2022
AMED Price
$117.21
Fair Value Price
$125.45
Market Cap
$3.82B
52 Week Low
$109.53
52 Week High
$276.21
P/E
20x
P/B
3.95x
P/S
2.52x
PEG
2.21x
Dividend Yield
N/A
Revenue
$2.22B
Earnings
$190.87M
Gross Margin
44.2%
Operating Margin
11.96%
Profit Margin
8.6%
Debt to Equity
0.92
Operating Cash Flow
$184M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AMED Overview
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMED scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMED ($117.21) is undervalued by 6.57% relative to our estimate of its Fair Value price of $125.45 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AMED ($117.21) is not significantly undervalued (6.57%) relative to our estimate of its Fair Value price of $125.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AMED ($117.21) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AMED due diligence checks available for Premium users.
AMED News
Valuation
AMED fair value
Fair Value of AMED stock based on Discounted Cash Flow (DCF)
Price
$117.21
Fair Value
$125.45
Undervalued by
6.57%
AMED ($117.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMED ($117.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMED ($117.21) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AMED price to earnings (PE)
For valuing profitable companies with steady earnings
Company
20x
Industry
9.85x
Market
21.67x
AMED is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AMED is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AMED price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.95x
Industry
4.55x
AMED is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMED price to earnings growth (PEG)
For valuing profitable companies with growth potential
AMED is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
AMED's financial health
Profit margin
Revenue
$545.3M
Net Income
$31.7M
Profit Margin
5.8%
AMED's Earnings (EBIT) of $265.67M... subscribe to Premium to read more.
Interest Coverage Financials
AMED's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.9B
Liabilities
$887.7M
Debt to equity
0.92
AMED's short-term assets ($392.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMED's long-term liabilities ($507.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMED's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AMED's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$48.6M
Investing
-$16.1M
Financing
-$7.4M
AMED's operating cash flow ($183.51M)... subscribe to Premium to read more.
Debt Coverage Financials
AMED vs Medical Care Facility Stocks
AMEDISYS Stock FAQ
©2022 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.